In the same cohort of melanoma patients treated with anti-PD-1 analyzed in (80), the authors observed a co-enrichment of CD8+ T cells with CSF-1 or various TAM-specific markers in pre-treatment biopsies of non-responders, suggesting that the recruitment of CD163+ M2-like macrophages by activated lymphocytes might be a mechanism of resistance to immunotherapy. The gene discussed is PDCD1; the disease is melanoma.